Microsoft research lead Doug Burger introduces his new podcast series, "The Shape of Things to Come", an exploration into the fundamental truths about AI and how the technology will reshape the future.
As the Women in Machine Learning Workshop (WiML) marks its 20th annual gathering, cofounders, friends, and collaborators Jenn Wortman Vaughan and Hanna Wallach reflect on WiML’s evolution, navigating the field of ML, and their work in responsible AI.
Microsoft’s Eric Horvitz and guests Bruce Wittmann, Tessa Alexanian, and James Diggans discuss the Paraphrase Project—a red-teaming effort that exposed and secured a biosecurity vulnerability in AI-driven protein design. The work offers a model for addressing AI’s dual-use risks.
For the series finale, Peter Lee, Carey Goldberg, and Dr. Zak Kohane compare their predictions to insights from the series’ most recent guests, including experts on AI’s economic and societal impact, leaders in AI-driven medicine, and doctors in training.
Former Washington State Secretary of Health Dr. Umair Shah and Mayo Clinic CEO Dr. Gianrico Farrugia explore how healthcare leaders are approaching AI when it comes to public health, care delivery, the healthcare-research connection, and the patient experience.
Next-generation physicians Morgan Cheatham and Daniel Chen discuss how generative AI is transforming medical education, exploring how students and attending physicians integrate new tools while navigating questions on trust, training, and responsibility.
In the series finale, Amanda Craig Deckard returns to examine what Microsoft has learned about testing as a governance tool. She also explores the roles of rigor, standardization, and interpretability in testing and what’s next for Microsoft’s AI governance work.
Drawing on his previous work as the UK’s cybersecurity chief, Professor Ciaran Martin explores differentiated standards and public-private partnerships in cybersecurity, and Microsoft’s Tori Westerhoff examines the insights through an AI red-teaming lens.
Daphne Koller, Noubar Afeyan, and Dr. Eric Topol, leaders in AI-driven medicine, discuss how AI is changing biomedical research and discovery, from accelerating drug target identification and biotech R&D to helping pursue the “holy grail” of a virtual cell.
Professors Daniel Carpenter and Timo Minssen explore evolving pharma and medical device regulation, including the role of clinical trials, while Microsoft applied scientist Chad Atalla shares where AI governance stakeholders might find inspiration in the fields.
Bioethics and law expert R. Alta Charo explores the value of regulating technologies at the application level and the role of coordinated oversight in genome editing, while Microsoft GM Daniel Kluttz reflects on Charo’s points, drawing parallels to AI governance.
In the introductory episode of this new series, host Kathleen Sullivan and Senior Director Amanda Craig Deckard explore Microsoft’s efforts to draw on the experience of other domains to help advance the role of AI testing and evaluation as a governance tool.
